In the last trading session, 1.34 million MoonLake Immunotherapeutics (NASDAQ:MLTX) shares changed hands as the company’s beta touched 1.32. With the company’s per share price at $40.18 changed hands at $1.03 or 2.63% during last session, the market valuation stood at $2.58B. MLTX’s last price was a discount, traded about -45.0% off its 52-week high of $58.26. The share price had its 52-week low at $31.42, which suggests the last value was 21.8% up since then. When we look at MoonLake Immunotherapeutics’s average trading volume, we note the 10-day average is 0.46 million shares, with the 3-month average coming to 408.15K.
Analysts gave the MoonLake Immunotherapeutics (MLTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended MLTX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. MoonLake Immunotherapeutics’s EPS for the current quarter is expected to be -0.75.
MoonLake Immunotherapeutics (NASDAQ:MLTX) trade information
Instantly MLTX was in green as seen at the end of in last trading. With action 1.85%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -25.80%, with the 5-day performance at 1.85% in the green. However, in the 30-day time frame, MoonLake Immunotherapeutics (NASDAQ:MLTX) is 0.80% up. Looking at the short shares, we see there were 6.63 million shares sold at short interest cover period of 12.63 days.
The consensus price target for the stock as assigned by Wall Street analysts is 67, meaning bulls need an upside of 40.03% from its current market value. According to analyst projections, MLTX’s forecast low is 67 with 67 as the target high. To hit the forecast high, the stock’s price needs a -66.75% plunge from its current level, while the stock would need to soar -66.75% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -319.65%. The 2025 estimates are for MoonLake Immunotherapeutics earnings to decrease by -60.96%, but the outlook for the next 5-year period is at -26.47% per year.
MLTX Dividends
MoonLake Immunotherapeutics is expected to release its next quarterly earnings report on 2025-Feb-25.
MoonLake Immunotherapeutics (NASDAQ:MLTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 15.43% of MoonLake Immunotherapeutics shares while 102.47% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 121.16%. There are 102.47% institutions holding the MoonLake Immunotherapeutics stock share, with BVF INC/IL the top institutional holder. As of 2024-06-30, the company held 34.7258% of the shares, roughly 21.75 million MLTX shares worth $956.4 million.
CORMORANT ASSET MANAGEMENT, LP holds the second largest percentage of outstanding shares, with 13.5609% or 8.49 million shares worth $373.49 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were T. Rowe Price Health Sciences Fund, Inc. and Fidelity Select Portfolios-Health Care Portfolio . With 1.56 shares estimated at $62.86 million under it, the former controlled 2.46% of total outstanding shares. On the other hand, Fidelity Select Portfolios-Health Care Portfolio held about 1.19% of the shares, roughly 752.79 shares worth around $30.25 million.
